Findlay Bewicke-Copley

13PUBLICATIONS
108CO-AUTHORS
Molecular targetsNeonatologyMolecular medicineHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 19, 2026
Replication origin firing capacity indicates ATR inhibitor sensitivity.

|Apr 09, 2025
DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.

Fadimana Kaya, Findlay Bewicke-Copley, Juho J Miettinen

|Aug 26, 2024
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation.

Vilma Dembitz, Hannah Lawson, Richard Burt

|Feb 13, 2024
Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma.

Danmei Xu, Findlay Bewicke-Copley, Karina Close

|Dec 09, 2022
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes.

Nerea Berastegui, Marina Ainciburu, Juan P Romero

|Sep 26, 2022
Germline ERCC excision repair 6 like 2 (ERCC6L2) mutations lead to impaired erythropoiesis and reshaping of the bone marrow microenvironment.

Hannah Armes, Findlay Bewicke-Copley, Ana Rio-Machin

Pageof 3

Frequent Collaborators

8 joint publications

Jude Fitzgibbon

7 joint publications

Ana Rio-Machin

6 joint publications

Jun Wang

5 joint publications

Kevin Rouault-Pierre